Previous 10 | Next 10 |
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Tr...
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse ® evaluation units to all thirty-two National Football League (“NFL”) teams. Alan Collier, CEO of Endon...
Los Angeles, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today that its previously announced 1-for-1,000 reverse split of its common stock will become effective as of December 19, 2019. Beginning on December 20, 20...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced that the company has determined to effect a 1-for-1,000 reverse stock split of its issued common shares. According to the update, the reverse stock split w...
Endonovo Therapeutics ( OTCQB:ENDV -33.3% ) announced it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. More news on: Endonovo Therapeutics, Inc., Healthcare stocks news, Read more ...
Los Angeles, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect,...
Revenues for the nine months ended September 30, 2019 also increased 293% to $161,720 Company is selling SofPulse(R), its noninvasive Electroceutical(R) therapeutic device, in 7 hospitals, 11 surgery centers and 14 other medical facilities The device is currently under evaluation in 112...
Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflam...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three mont...
Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30, 2019. Key Financial Highlights: Revenues for the three months ended September 30, 2019...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...